Replies to post #323460 on Avid Bioservices Inc (CDMO)

[biopharm]

Is this Xencor Xmab5871 infringing upon PS Targeting IP rights? I say YES and this is why we must ask the new BODs to make damn sure they protect the IP assets and KNOWING the details of Steve Demattos departure, his confidentiality agreement, his deposition in relation to the sabotage by CSM who had CEO Gerald Finken and his sidekick Jeanette Bleecker that we know already admitted swapping and sabotaging the Peregrine trial....is critical to realizing the true value of the PS Targeting IP at Peregrine, now called Avid Bioservices.

Ask the new BODs why they are not getting all this information and making it known to the public and all shareholders.....as they can't keep it a secret when they get requests via certified letters.

XmAb5871 is a first-in-class monoclonal antibody that targets CD19 with its variable domain and uses the XmAb immune inhibitory Fc domain to target Fc?RIIb, a receptor that inhibits B cell function. XmAb5871 is the first drug candidate to our knowledge that targets Fc?RIIb inhibition.

Yes, Xencor to their knowledge MAY now know PS Targeting rights are being infringed upon....

If everyone does not resend certified letters and question EVERYTHING ....then we will see breadcrumb nothing in return for the sale or license of the PS Targeting platform

Seek the answers

Now

What happens first, the targeting of flipped PS, THEN the downstream changes ....and the new BODs are 100% responsible for Fiduciary Duties in the handling and protection of our assets, including their #1 assets of PS Targeting, which includes much of the sealed records past.....where it would be inconceivable that they could possibly make a rational decision on any true value of PS Targeting till all questions are answered and if that makes no sense to them....well then, maybe we have more than enough mentally unstable minds in charge of the PS Targeting IP rights, that may need to be removed from their duties??

This is simple re: that PS Targeting is upstream....global.....and just because it was difficult to realize the power of PS Targeting in the past does not mean one has to hand it over for breadcrumbs if promised a well funded CDMO operation. What would a jury say once all sealed records were read to them....once all depositions become public knowledge.....once all certified letters become public ? Once email after email was disclosed .....and it begins to become a bit mind boggling in how the new BODs would not take this more seriously than it seems, as Dr Roger Lias thinks it will blow over or maybe he was told that....

p85a recruitment by the CD300f phosphatidylserine receptor mediates apoptotic cell clearance required for autoimmunity suppression.

p85a recruitment by the CD300f phosphatidylserine receptor mediates apoptotic cell clearance required for autoimmunity suppression.
Linjie Tian, Seung-Chul Choi, +5 authors John E. ColiganNature communications2014

View on PubMed

Abstract
Apoptotic cell (AC) clearance is essential for immune homeostasis. Here we show that mouse CD300f (CLM-1) recognizes outer membrane-exposed phosphatidylserine, and regulates the phagocytosis of ACs. CD300f accumulates in phagocytic cups at AC contact sites. Phosphorylation within CD300f cytoplasmic tail tyrosine-based motifs initiates signals that positively or negatively regulate AC phagocytosis. Y276 phosphorylation is necessary for enhanced CD300f-mediated phagocytosis through the recruitment of the p85a regulatory subunit of phosphatidylinositol-3-kinase (PI3K). CD300f-PI3K association leads to activation of downstream Rac/Cdc42 GTPase and mediates changes of F-actin that drive AC engulfment. Importantly, primary macrophages from CD300f-deficient mice have impaired phagocytosis of ACs. The biological consequence of CD300f deficiency is predisposition to autoimmune disease development, as Fc?RIIB-deficient mice develop a systemic lupus erythematosus-like disease at a markedly accelerated rate if CD300f is absent. In this report we identify the mechanism and role of CD300f in AC phagocytosis and maintenance of immune homeostasis.
...
...

https://www.semanticscholar.org/paper/p85a-recruitment-by-the-CD300f-phosphatidylserine-Tian-Choi/0cf029bab0d343bf988266b9bb33861454159c99

The Biology and Disease Relevance of CD300a, an Inhibitory Receptor for Phosphatidylserine and Phosphatidylethanolamine
Olatz Zenarruzabeitia, Joana Vitallé, Cristina Eguizabal, Venkateswara R. Simhadri and Francisco Borrego
J Immunol June 1, 2015, 194 (11) 5053-5060; DOI: https://doi.org/10.4049/jimmunol.1500304
....
....

A recent study reported that the interaction between CD300a and PS inhibits tumor cell killing by NK cells (11). Several studies showed that, in the tumor microenvironment, there is a significant stress imposed on the tumor endothelium by acidity, reactive oxygen species, and transient hypoxia, which result in the redistribution and exposure of PS and PE (84). Indeed, expression of PS was detected in gastric carcinoma (85), ovarian carcinoma (86), and melanoma (87). Recent data support that the binding of CD300a-Ig to tumor cells is reduced when PS is blocked and that the blocking of PS enhances NK cell–mediated cytotoxicity. Blocking of PS partially restored NK cell cytotoxicity, indicating that tumor cells express an additional ligand for CD300a (11). This additional ligand might be PE, which also was shown to be a ligand for CD300a (13, 38). Therefore, a new tumor immune-evasion mechanism was suggested to be mediated through the interaction between PS and PE on tumor cells and CD300a on cytotoxic lymphocytes.
...
...

http://www.jimmunol.org/content/194/11/5053

[biopharm]

WestJttr are you positive the value driver is not PS Targeting milestones and royalties and other drugs that possibly infringe upon PS Targeting IP rights ?

Namtro, have you emailed concern to Xencor with their relationships with some BPs like Merck?

One never knows what may happen and when we officially see now proof of BP collusion with drug prices, wouldn't they also collude to steer PS Targeting certain ways?

SOME will like to sell off Avid "before .." anyone has any idea the true magnitude of worth of PS Targeting to Biomarkers to MRIs to blood brain barrier flipping PS entries etc

[biopharm]

John Springs Stafford feeling the heat and more is coming..

All should realize Steve Demattos has a very close tie with Ronald Bradley Demattos so why has the new BOD NOT done their fiduciary duties and look into everything as now they are officially going to be placed on warning that some are trying awfully hard to conceal the true value of the IP surrounding PS Targeting / biomarkers etc

Let us review and as you weave thru the puzzle pieces, Merck has an objective and it is to pick up all of PS Targeting IP value driver biomarkers via others help and that would be illegal to manipulate stock prices as John Springs Stafford is well aware

________

David M Holtzman on patents with Cheryl Leyns who is poached by Merck and yes, more to come

The new BODs have fiduciary duties to extract all values ...all avenues ...to maximize shareholder value and someone wants to buy out a CDMO because some want to HIDE the IP asset valuations behind biomarkers etc

Don't let it happen and all send in to IR that this is not acceptable

A bonus for you all: Heather Preston and David Preston ...some of it mentioned before but ties from Pivotal Bioventures to Advent International

https://www.adventinternational.com/bioduro-partners-with-advent-international/

First things first though.... the FBI investigations looked long into the DeMattos ...I certainly hope they are smarter than I

_________

No public announcement from the new BODs in regards to Steve Demattos departure of Pergrine Pharmaceuticals ? No excuse because the new BODs CAN NOT use the excuse that what happened in the past has no bearing now because it certainly matters. It matters because who knows what was concealed in the depositions or what trade secrets were use with Steve Demattos over at Xencor now ....the same Xencor and here John Stafford has left their BOD but buying up alot of Xencor stock this past year.....which all coincides with Stafford / Steve White with Ronin Hedge Group as it seems they are trying to conceal the true value of PS Targeting IP ...

Steve Demattos listed as contact for Xencor trial
Contact: Steve DeMattos, BS 858-480-3892 [e-mail]
https://clinicaltrials.gov/ct2/show/NCT02725515

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138048080

_______

Ronald Bradley Demattos
age 49
Get Full Report on Ronald

ADDRESS HISTORY

Zionsville, IN
Fishers, IN
Noblesville, IN
Indianapolis, IN
Saint Louis, MO
Centereach, NY
Stony Brook, NY
East Setauket, NY
Port Jefferson Station, NY
Northville, MI

RELATIVES

Matthew Demattos
Yvonne Demattos
Abel Demattos
Steven Demattos
Alyssa Demattos
David Demattos
Shong Demattos

_________

Ronald DeMattos
Chief Scientific Officer Neurobiologics and Indianapolis Neuroscience Site Leader at Eli Lilly and Company
Indianapolis, Indiana Area
Pharmaceuticals500+

Summary
Ronald B. DeMattos, Ph.D. is currently a Chief Scientific Officer for Neurobiologics and Indianapolis Neuroscience Site Leader at Eli Lilly and Company. Dr. DeMattos received his doctorate in molecular and cellular biochemistry from State University of New York â?? Stony Brook in 1998. During his post-doctoral fellowship at Washington University School of Medicine (laboratory of David M. Holtzman), Dr. DeMattos performed the foundational studies that led to the development of the peripheral sink hypothesis for Alzheimerâ??s immunotherapy as well as the original antibody studies that would eventually lead to Eli Lillyâ??s Phase III drug candidate Solanezumab. Dr. DeMattos was recruited to Eli Lilly as a Research Scientist in 2002 and he has subsequently been promoted six times. He has led multiple successful programs targeting Alzheimerâ??s disease (compounds in Phase-1 and Phase-3) and he has played a major role in expanding the immunotherapy platform. Under Dr. DeMattosâ??s leadership, his team has provided many important deliverables for the Neuroscience division wherein they have developed scientific rationale, identified biomolecules, developed and performed innovative SAR, delivered key proof of concept data, and championed several large molecules through all phases of development (one of which is currently in Phase III clinical trials). Dr. DeMattos has developed the scientific rationale and corresponding assays to support clinical biomarker studies (7 different validated biomarker assays have been utilized in the clinic). Dr. DeMattos has played a key role in developing Lillyâ??s Alzheimerâ??s strategy and he has been a key resource for numerous functions beyond discovery. Dr. DeMattos currently leads the Indianapolis Neuroscience site comprised of talented scientists and staff whose mission is to develop novel first-in class therapies for Neuroscience indications, with significant emphasis on neurodegeneration and Alzheimerâ??s disease.

Specialties: Alzheimer's disease, drug development, clinical biomarker development, preclinical to clinical translational studies, in vivo pharmacology, lipoprotein biology, immunotherapy, pharmacology and biochemistry,
Experience
Image for Chief Scientific Officer Neurobiologics and Indianapolis Neuroscience Site Leader
Chief Scientific Officer Neurobiologics and Indianapolis Neuroscience Site Leader
Eli Lilly and Company
June 2002 â?? Present 17 years 1 month
Image for Instructer in Neurology
Instructer in Neurology
Washington University School of Medicine
June 1999 â?? June 2002 3 years 1 month

People also viewed

J. Carmel Egan
Associate Dean for Research Affairs , IU School of Medicine and COO Indiana CTSI

Henry Bryant
Distinguished Research Fellow at Lilly Research Laboratories

Janelle Sabo
Global Head, Product Delivery at Eli Lilly and Company

Bradley Miller MD, PhD
Senior Managing Director in Neuroscience

Charles Mitch
Eli Lilly (retired)

Jeffrey Witkin
Chief Executive Officer at Witkin Consulting Group

Patrick May
President at ADvantage Neuroscience Consulting LLC

Juan Jose Carrillo
Director at Eli Lilly and Company

Francis Willard
Research Scientist at LRL

Larry Blaszczak
Independent Pharmaceutical Consultant, Indianapolis Indiana Area.

_______

Top co-authors (50)

David M Holtzman
Washington University in St. Louis

Steven M Paul

Kelly Bales
Roche Pharma Research & Early Development

Margaret M. Racke

Robert A Dean
Eli Lilly

Affiliations
Eli Lilly and Company

United States Naval Research Laboratory

Philipps University of Marburg

University of Illinois at Chicago

Indianapolis Zoo

University of British Columbia - Vancouver
Department
Department of Pathology and Laboratory Medicine

Columbia University

Eli Lilly
Department
Lilly Research Laboratories

Duke University
Department
Department of Medicine

Indiana University-Purdue University Indianapolis
Department
Department of Psychiatry

Carnegie Mellon University
Department
Department of Chemistry

Washington University in St. Louis
Department
Department of Neurology

University of California, San Diego

State University of New York

Hackensack University Medical Center

Massachusetts Institute of Technology
Department
Department of Biology

https://www.google.com/amp/s/www.researchgate.net/scientific-contributions/39737839_Ronald_B_DeMattos/amp

[Globewriter]

A message remembered

Is this Xencor Xmab5871 infringing upon PS Targeting IP rights? I say YES and this is why we must ask the new BODs to make damn sure they protect the IP assets and KNOWING the details of Steve Demattos departure, his confidentiality agreement, his deposition in relation to the sabotage by CSM who had CEO Gerald Finken and his sidekick Jeanette Bleecker that we know already admitted swapping and sabotaging the Peregrine trial....is critical to realizing the true value of the PS Targeting IP at Peregrine, now called Avid Bioservices.

Nicholas Green CEO Peregrine Pharmaceuticals / Avid Bioservices - knows he stands in a crossroad and Turning Point where he goes in Rhythm to maximize shareholder value fast- not sure if he should side with David Meeker though ....” what will Bamforth and Walsh suggest ?